Cargando…
Efficacy and safety of rivaroxaban versus placebo after lower extremity bypass surgery: A post hoc analysis of a “CASPAR like” outcome from VOYAGER PAD
BACKGROUND: The Clopidogrel and Acetylsalicylic Acid in Bypass Surgery for Peripheral Arterial Disease (CASPAR) trial is the only large, double‐blind, placebo‐controlled trial of dual antiplatelet therapy (DAPT) versus aspirin in patients with peripheral artery disease (PAD) after lower extremity re...
Autores principales: | Bonaca, Marc P., Szarek, Michael, Debus, E. Sebastian, Nehler, Mark R., Patel, Manesh R., Anand, Sonia S., Muehlhofer, Eva, Berkowitz, Scott D., Haskell, Lloyd P., Bauersachs, Rupert M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9748742/ https://www.ncbi.nlm.nih.gov/pubmed/36251249 http://dx.doi.org/10.1002/clc.23926 |
Ejemplares similares
-
Sex‐Based Differences in Outcomes Following Peripheral Artery Revascularization: Insights From VOYAGER PAD
por: Hess, Connie N., et al.
Publicado: (2022) -
Prevention of arterial and venous thrombotic events in symptomatic peripheral arterial disease patients after lower extremity revascularization in the VOYAGER PAD trial: Dual anticoagulant/antiplatelet regimen vs antiplatelet therapy alone
por: Berkowitz, Scott D., et al.
Publicado: (2022) -
Rivaroxaban and Risk of Venous Thromboembolism in Patients With Symptomatic Peripheral Artery Disease After Lower Extremity Revascularization
por: Hess, Connie N., et al.
Publicado: (2022) -
Background/CASPAR study
por: Tait, Diana
Publicado: (2015) -
Caspar Wistar, Junior
por: Middleton, William Shainline
Publicado: (1922)